Agile Therapeutics, Inc. (NASDAQ:AGRX) - Investment analysts at Zacks Investment Research decreased their Q3 2017 earnings estimates for shares of Agile Therapeutics in a report issued on Monday. Zacks Investment Research analyst D. Bautz now forecasts that the specialty pharmaceutical company will earn ($0.26) per share for the quarter, down from their prior estimate of ($0.25). Zacks Investment Research also issued estimates for Agile Therapeutics’ Q4 2017 earnings at ($0.25) EPS.
Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.02. During the same period last year, the firm earned ($0.29) EPS.
Other research analysts have also recently issued reports about the stock. Cantor Fitzgerald reissued a “buy” rating and set a $9.00 price target on shares of Agile Therapeutics in a report on Monday, May 8th. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a report on Wednesday, June 14th. Janney Montgomery Scott reissued a “buy” rating and set a $15.00 price target on shares of Agile Therapeutics in a report on Friday, July 21st. HC Wainwright initiated coverage on shares of Agile Therapeutics in a report on Wednesday, July 19th. They set a “buy” rating and a $10.00 price target for the company. Finally, Royal Bank Of Canada set a $8.00 price target on shares of Agile Therapeutics and gave the stock a “buy” rating in a report on Sunday, July 16th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Agile Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $9.93.
Shares of Agile Therapeutics (AGRX) opened at 4.57 on Wednesday. Agile Therapeutics has a 52-week low of $1.82 and a 52-week high of $8.15. The stock’s 50 day moving average price is $4.15 and its 200-day moving average price is $3.21. The firm’s market capitalization is $131.64 million.
In related news, Chairman Alfred Altomari bought 10,000 shares of the stock in a transaction on Thursday, May 11th. The shares were bought at an average cost of $3.51 per share, for a total transaction of $35,100.00. Following the completion of the transaction, the chairman now owns 151,587 shares of the company’s stock, valued at approximately $532,070.37. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Renee Selman bought 53,333 shares of the stock in a transaction on Thursday, May 11th. The shares were bought at an average price of $3.68 per share, for a total transaction of $196,265.44. Following the completion of the transaction, the insider now directly owns 53,333 shares of the company’s stock, valued at approximately $196,265.44. The disclosure for this purchase can be found here. Corporate insiders own 3.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its position in shares of Agile Therapeutics by 209.2% in the fourth quarter. Renaissance Technologies LLC now owns 64,000 shares of the specialty pharmaceutical company’s stock valued at $365,000 after buying an additional 43,300 shares during the last quarter. Royce & Associates LP raised its position in shares of Agile Therapeutics by 206.1% in the first quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock valued at $3,165,000 after buying an additional 665,000 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in shares of Agile Therapeutics during the second quarter valued at $122,000. Institutional investors own 79.77% of the company’s stock.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
